Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update
Lung cancer (LC) is the leading cause of cancer-related deaths, responsible for approximately 18.4% of all cancer mortalities in both sexes combined. The use of systemic therapeutics remains one of the primary treatments for LC. However, the therapeutic efficacy of these agents is limited due to the...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/8/725 |
id |
doaj-aaba251449bc4f569ff2718d7a285f46 |
---|---|
record_format |
Article |
spelling |
doaj-aaba251449bc4f569ff2718d7a285f462021-08-26T14:12:09ZengMDPI AGPharmaceuticals1424-82472021-07-011472572510.3390/ph14080725Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An UpdateIbrahim M. Abdulbaqi0Reem Abou Assi1Anan Yaghmur2Yusrida Darwis3Noratiqah Mohtar4Thaigarajan Parumasivam5Fadi G. Saqallah6Habibah A. Wahab7School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaDepartment of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen Ø, DenmarkSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, MalaysiaLung cancer (LC) is the leading cause of cancer-related deaths, responsible for approximately 18.4% of all cancer mortalities in both sexes combined. The use of systemic therapeutics remains one of the primary treatments for LC. However, the therapeutic efficacy of these agents is limited due to their associated severe adverse effects, systemic toxicity and poor selectivity. In contrast, pulmonary delivery of anticancer drugs can provide many advantages over conventional routes. The inhalation route allows the direct delivery of chemotherapeutic agents to the target LC cells with high local concertation that may enhance the antitumor activity and lead to lower dosing and fewer systemic toxicities. Nevertheless, this route faces by many physiological barriers and technological challenges that may significantly affect the lung deposition, retention, and efficacy of anticancer drugs. The use of lipid-based nanocarriers could potentially overcome these problems owing to their unique characteristics, such as the ability to entrap drugs with various physicochemical properties, and their enhanced permeability and retention (EPR) effect for passive targeting. Besides, they can be functionalized with different targeting moieties for active targeting. This article highlights the physiological, physicochemical, and technological considerations for efficient inhalable anticancer delivery using lipid-based nanocarriers and their cutting-edge role in LC treatment.https://www.mdpi.com/1424-8247/14/8/725lung cancertargeted drug deliverylipid-based nanocarrierspulmonary deliverydry powder inhalersaerosols |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ibrahim M. Abdulbaqi Reem Abou Assi Anan Yaghmur Yusrida Darwis Noratiqah Mohtar Thaigarajan Parumasivam Fadi G. Saqallah Habibah A. Wahab |
spellingShingle |
Ibrahim M. Abdulbaqi Reem Abou Assi Anan Yaghmur Yusrida Darwis Noratiqah Mohtar Thaigarajan Parumasivam Fadi G. Saqallah Habibah A. Wahab Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update Pharmaceuticals lung cancer targeted drug delivery lipid-based nanocarriers pulmonary delivery dry powder inhalers aerosols |
author_facet |
Ibrahim M. Abdulbaqi Reem Abou Assi Anan Yaghmur Yusrida Darwis Noratiqah Mohtar Thaigarajan Parumasivam Fadi G. Saqallah Habibah A. Wahab |
author_sort |
Ibrahim M. Abdulbaqi |
title |
Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update |
title_short |
Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update |
title_full |
Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update |
title_fullStr |
Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update |
title_full_unstemmed |
Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update |
title_sort |
pulmonary delivery of anticancer drugs via lipid-based nanocarriers for the treatment of lung cancer: an update |
publisher |
MDPI AG |
series |
Pharmaceuticals |
issn |
1424-8247 |
publishDate |
2021-07-01 |
description |
Lung cancer (LC) is the leading cause of cancer-related deaths, responsible for approximately 18.4% of all cancer mortalities in both sexes combined. The use of systemic therapeutics remains one of the primary treatments for LC. However, the therapeutic efficacy of these agents is limited due to their associated severe adverse effects, systemic toxicity and poor selectivity. In contrast, pulmonary delivery of anticancer drugs can provide many advantages over conventional routes. The inhalation route allows the direct delivery of chemotherapeutic agents to the target LC cells with high local concertation that may enhance the antitumor activity and lead to lower dosing and fewer systemic toxicities. Nevertheless, this route faces by many physiological barriers and technological challenges that may significantly affect the lung deposition, retention, and efficacy of anticancer drugs. The use of lipid-based nanocarriers could potentially overcome these problems owing to their unique characteristics, such as the ability to entrap drugs with various physicochemical properties, and their enhanced permeability and retention (EPR) effect for passive targeting. Besides, they can be functionalized with different targeting moieties for active targeting. This article highlights the physiological, physicochemical, and technological considerations for efficient inhalable anticancer delivery using lipid-based nanocarriers and their cutting-edge role in LC treatment. |
topic |
lung cancer targeted drug delivery lipid-based nanocarriers pulmonary delivery dry powder inhalers aerosols |
url |
https://www.mdpi.com/1424-8247/14/8/725 |
work_keys_str_mv |
AT ibrahimmabdulbaqi pulmonarydeliveryofanticancerdrugsvialipidbasednanocarriersforthetreatmentoflungcanceranupdate AT reemabouassi pulmonarydeliveryofanticancerdrugsvialipidbasednanocarriersforthetreatmentoflungcanceranupdate AT ananyaghmur pulmonarydeliveryofanticancerdrugsvialipidbasednanocarriersforthetreatmentoflungcanceranupdate AT yusridadarwis pulmonarydeliveryofanticancerdrugsvialipidbasednanocarriersforthetreatmentoflungcanceranupdate AT noratiqahmohtar pulmonarydeliveryofanticancerdrugsvialipidbasednanocarriersforthetreatmentoflungcanceranupdate AT thaigarajanparumasivam pulmonarydeliveryofanticancerdrugsvialipidbasednanocarriersforthetreatmentoflungcanceranupdate AT fadigsaqallah pulmonarydeliveryofanticancerdrugsvialipidbasednanocarriersforthetreatmentoflungcanceranupdate AT habibahawahab pulmonarydeliveryofanticancerdrugsvialipidbasednanocarriersforthetreatmentoflungcanceranupdate |
_version_ |
1721190773322416128 |